glp 1 and ampk Metformin Glucagon-like peptide-1 (GLP-1) inhibit Adenosine ampk glp 1 Frontiers

Jensen H, Potempa M, Gotthardt D, Lanier LL

Glossary AUD alcohol-use disorder CD Chron's disease CLBP chronic low back pain CNPV Commissioner's National Priority Voucher CV cardiovascular CVD cardiovascular disease FDA Food and Drug Administration GIP glucose-dependent insulinotropic polypeptide GLP-1 glucagon-like peptide-1 GLP-1s glucagon-like peptide-1 receptor agonists HTN hypertension MACE major adverse cardiovascular events MASH metabolic dysfunction-associated steatohepatitis OA osteoarthritis OSA obstructive sleep apnea PsA psoriatic arthritis PSO psoriatic arthritis SC subcutaneous SGLT2i sodium-glucose co-transporter 2 inhibitor T1DM type 1 diabetes mellitus T2DM type 2 diabetes mellitus UC ulcerative colitis U.S

PMCID: PMC5855206

Treatment plans vary in dosing, frequency, and duration depending on the type of injury, severity, and your overall clinical profile